Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Relmada Therapeutics Inc.

    NASDAQ: RLMD · Real-Time Price · USD
    0.60
    -0.02 (-2.61%)
    At close: Jul 02, 2025, 3:59 PM
    0.61
    1.19%
    After-hours: Jul 02, 2025, 04:47 PM EDT

    Relmada Therapeutics Statistics

    Share Statistics

    Relmada Therapeutics has 33.19M shares outstanding. The number of shares has increased by 10% in one year.

    Shares Outstanding

    n/a
    		 33.19M

    Shares Change (YoY)

    n/a
    		 10%

    Shares Change (QoQ)

    n/a
    		 10%

    Owned by Institutions (%)

    n/a
    		 27.84%

    Shares Floating

    n/a
    		 26.73M

    Failed to Deliver (FTD) Shares

    n/a
    		 31

    FTD / Avg. Volume

    n/a
    		 n/a

    Short Selling Information

    The latest short interest is 695.46K, so 2.1% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 695.46K

    Short % of Shares Out

    n/a
    		 2.1%

    Short % of Float

    n/a
    		 2.14%

    Short Ratio (days to cover)

    n/a
    		 1.55

    Valuation Ratios

    The PE ratio is -0.2 and the forward PE ratio is -0.61. Relmada Therapeutics's PEG ratio is 0.01.

    PE Ratio

    n/a
    		 -0.2

    Forward PE

    n/a
    		 -0.61

    PS Ratio

    n/a
    		 0

    Forward PS

    n/a
    		 n/a

    PB Ratio

    n/a
    		 0.44

    P/FCF Ratio

    n/a
    		 -0.3

    PEG Ratio

    n/a
    		 0.01
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Relmada Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 4.45, with a Debt / Equity ratio of 0.

    Current Ratio

    n/a
    		 4.45

    Quick Ratio

    n/a
    		 4.45

    Debt / Equity

    n/a
    		 0

    Debt / EBITDA

    n/a
    		 n/a

    Debt / FCF

    n/a
    		 n/a

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 n/a

    Profits Per Employee

    n/a
    		 $-4,704,647.06

    Employee Count

    n/a
    		 17

    Asset Turnover

    n/a
    		 0

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 n/a

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by -17.06% in the last 52 weeks. The beta is 0.66, so Relmada Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 0.66

    52-Week Price Change

    n/a
    		 -17.06%

    50-Day Moving Average

    n/a
    		 0.58

    200-Day Moving Average

    n/a
    		 0.54

    Relative Strength Index (RSI)

    n/a
    		 48

    Average Volume (20 Days)

    n/a
    		 1,853,040

    Income Statement

    Revenue

    n/a
    		 n/a

    Gross Profit

    n/a
    		 n/a

    Operating Income

    n/a
    		 -83.89M

    Net Income

    n/a
    		 -79.98M

    EBITDA

    n/a
    		 -79.98M

    EBIT

    n/a
    		 -79.98M

    Earnings Per Share (EPS)

    n/a
    		 -2.65
    Full Income Statement

    Balance Sheet

    The company has 3.86M in cash and 0 in debt, giving a net cash position of 3.86M.

    Cash & Cash Equivalents

    n/a
    		 3.86M

    Total Debt

    n/a
    		 n/a

    Net Cash

    n/a
    		 n/a

    Retained Earnings

    n/a
    		 -640.88M

    Total Assets

    n/a
    		 27.68M

    Working Capital

    n/a
    		 22.43M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -51.76M and capital expenditures 0, giving a free cash flow of -51.76M.

    Operating Cash Flow

    n/a
    		 -51.76M

    Capital Expenditures

    n/a
    		 n/a

    Free Cash Flow

    n/a
    		 -51.76M

    FCF Per Share

    n/a
    		 -1.72
    Full Cash Flow Statement

    Margins

    Gross Margin

    n/a
    		 n/a

    Operating Margin

    n/a
    		 n/a

    Pretax Margin

    n/a
    		 n/a

    Profit Margin

    n/a
    		 n/a

    EBITDA Margin

    n/a
    		 n/a

    EBIT Margin

    n/a
    		 n/a

    FCF Margin

    n/a
    		 n/a

    Dividends & Yields

    RLMD does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for RLMD is $1, which is 61.3% higher than the current price. The consensus rating is "Hold".

    Price Target

    n/a
    		 $1

    Price Target Difference

    n/a
    		 61.3%

    Analyst Consensus

    n/a
    		 Hold

    Analyst Count

    n/a
    		 3
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Stock Splits

    The last stock split was on Sep 30, 2019. It was a backward split with a ratio of 1:4.

    Last Split Date

    n/a
    		 Sep 30, 2019

    Split Type

    n/a
    		 backward

    Split Ratio

    n/a
    		 1:4

    Scores

    Altman Z-Score

    n/a
    		 -41.26

    Piotroski F-Score

    n/a
    		 1

    Add to Watchlist